

Docket No.: 58086-232451
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Charles L. SAWYERS et al.

Art Unit: 1642

Application No: 10/583,280

Examiner: Sean E. Aeder

Confirmation No: 2639

Filed: June 16, 2006

Atty. Docket No: 58086-232451

For: METHODS AND MATERIALS FOR
ASSESSING PROSTATE CANCER
THERAPIES

Customer No:

26694
PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of a first Office Action, but before the mailing date of a final Action or a Notice of Allowance as far as is known to the undersigned (37 CFR 1.97(c)). The Director is hereby authorized to charge the fee of \$180 due under 37 CFR 1.17(p) and 1.97(c)(2) to Deposit Account No. 22-0261, under Order No. 58086-232451.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2). Copies of **Documents**

B8-B9, B11-B31, B33-37, B39-B44, C90-C92, C94-C96, C98-C135, and C143 are enclosed.

Document **B17**, in the English language, is understood to be a European regional phase of the published international application **B11**, in the Japanese language.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed documents.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 58086-232451.

Respectfully submitted,

Dated: *MARCH 17, 2010*

By 
Lars H. Genieser
Registration No.: 46,722
VENABLE LLP
P.O. Box 34385
Washington, DC 20043-9998
(202) 344-4000
(202) 344-8300 (Fax)
Attorney/Agent For Applicant

DC2/1032178